rabbit monoclonal anti phospho chk1 ser 345  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc rabbit monoclonal anti phospho chk1 ser 345
    HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, <t>CHK1,</t> CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .
    Rabbit Monoclonal Anti Phospho Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal anti phospho chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit monoclonal anti phospho chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors"

    Article Title: Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors

    Journal: EMBO Reports

    doi: 10.1038/s44319-024-00089-7

    HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .
    Figure Legend Snippet: HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .

    Techniques Used: Western Blot, Cell Culture, Comparison

    Reagents and tools.
    Figure Legend Snippet: Reagents and tools.

    Techniques Used: Membrane, Modification, Protease Inhibitor, Software, Bicinchoninic Acid Protein Assay, Viability Assay

    phospho chk1 ser 345  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc phospho chk1 ser 345
    Phospho Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    phospho chk1 ser 345  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc phospho chk1 ser 345
    ( A ) WT or E6AP knockout (KO) HeLa cells were treated with or without MASTL siRNA. The cells were incubated in 0.1 μM etoposide (ETO) for 18 hr, and released in fresh medium for recovery. Cells were harvested at the indicated time points (after the removal of ETO) for immunofluorescence (IF) using an anti-phospho-Aurora A/B/C antibody. The activation of Aurora phosphorylation (shown in red) and chromosome condensation (in blue) indicated mitosis. The percentages of cells in mitosis were quantified manually and shown. The mean values and standard deviations were calculated from three experiments. An unpaired two-tailed Student’s t test was used to determine the statistical significance (*p<0.05, **p<0.01, n>500 cell number/measurement). MASTL knockdown by siRNA was shown by immunoblotting in the panel E. ( B ) WT or E6AP KO HeLa cells with or without MASTL siRNA, as in panel A, were treated with 2 mM hydroxyurea (HU) for 18 hr. Cells were then released in fresh medium, and incubated as indicated, for recovery. The cell cycle progression was analyzed by fluorescence-activated cell sorting (FACS), as described in Materials and methods. ( C ) WT or E6AP KO HeLa cells were treated with or without 0.5 μM doxorubicin (DOX) for 4 hr. Cells were then analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, phospho-SMC1 <t>Ser-957,</t> <t>phospho-CHK1</t> <t>Ser-345,</t> phospho-CHK2 Thr-68, γ-H2AX, and α-tubulin. ( D ) WT, E6AP KO, or E6AP KO with expression of HA-E6AP HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, and α-tubulin. ( E ) WT, E6AP KO, or E6AP KO with transfection of MASTL siRNA HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for MASTL, phospho-ATM/ATR substrates, and α-tubulin.
    Phospho Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "The ATM-E6AP-MASTL axis mediates DNA damage checkpoint recovery"

    Article Title: The ATM-E6AP-MASTL axis mediates DNA damage checkpoint recovery

    Journal: eLife

    doi: 10.7554/eLife.86976

    ( A ) WT or E6AP knockout (KO) HeLa cells were treated with or without MASTL siRNA. The cells were incubated in 0.1 μM etoposide (ETO) for 18 hr, and released in fresh medium for recovery. Cells were harvested at the indicated time points (after the removal of ETO) for immunofluorescence (IF) using an anti-phospho-Aurora A/B/C antibody. The activation of Aurora phosphorylation (shown in red) and chromosome condensation (in blue) indicated mitosis. The percentages of cells in mitosis were quantified manually and shown. The mean values and standard deviations were calculated from three experiments. An unpaired two-tailed Student’s t test was used to determine the statistical significance (*p<0.05, **p<0.01, n>500 cell number/measurement). MASTL knockdown by siRNA was shown by immunoblotting in the panel E. ( B ) WT or E6AP KO HeLa cells with or without MASTL siRNA, as in panel A, were treated with 2 mM hydroxyurea (HU) for 18 hr. Cells were then released in fresh medium, and incubated as indicated, for recovery. The cell cycle progression was analyzed by fluorescence-activated cell sorting (FACS), as described in Materials and methods. ( C ) WT or E6AP KO HeLa cells were treated with or without 0.5 μM doxorubicin (DOX) for 4 hr. Cells were then analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, phospho-SMC1 Ser-957, phospho-CHK1 Ser-345, phospho-CHK2 Thr-68, γ-H2AX, and α-tubulin. ( D ) WT, E6AP KO, or E6AP KO with expression of HA-E6AP HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, and α-tubulin. ( E ) WT, E6AP KO, or E6AP KO with transfection of MASTL siRNA HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for MASTL, phospho-ATM/ATR substrates, and α-tubulin.
    Figure Legend Snippet: ( A ) WT or E6AP knockout (KO) HeLa cells were treated with or without MASTL siRNA. The cells were incubated in 0.1 μM etoposide (ETO) for 18 hr, and released in fresh medium for recovery. Cells were harvested at the indicated time points (after the removal of ETO) for immunofluorescence (IF) using an anti-phospho-Aurora A/B/C antibody. The activation of Aurora phosphorylation (shown in red) and chromosome condensation (in blue) indicated mitosis. The percentages of cells in mitosis were quantified manually and shown. The mean values and standard deviations were calculated from three experiments. An unpaired two-tailed Student’s t test was used to determine the statistical significance (*p<0.05, **p<0.01, n>500 cell number/measurement). MASTL knockdown by siRNA was shown by immunoblotting in the panel E. ( B ) WT or E6AP KO HeLa cells with or without MASTL siRNA, as in panel A, were treated with 2 mM hydroxyurea (HU) for 18 hr. Cells were then released in fresh medium, and incubated as indicated, for recovery. The cell cycle progression was analyzed by fluorescence-activated cell sorting (FACS), as described in Materials and methods. ( C ) WT or E6AP KO HeLa cells were treated with or without 0.5 μM doxorubicin (DOX) for 4 hr. Cells were then analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, phospho-SMC1 Ser-957, phospho-CHK1 Ser-345, phospho-CHK2 Thr-68, γ-H2AX, and α-tubulin. ( D ) WT, E6AP KO, or E6AP KO with expression of HA-E6AP HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, and α-tubulin. ( E ) WT, E6AP KO, or E6AP KO with transfection of MASTL siRNA HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for MASTL, phospho-ATM/ATR substrates, and α-tubulin.

    Techniques Used: Knock-Out, Incubation, Immunofluorescence, Activation Assay, Two Tailed Test, Western Blot, Fluorescence, FACS, Expressing, Transfection

    ( A ) HeLa cells expressing CFP-MASTL were treated without or with 10 mM hydroxyurea (HU) for 2 hr. CFP-MASTL immunoprecipitation (IP) was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, and β-actin. ( B ) HeLa cells expressing CFP-MASTL were treated without or with 10 mM HU and 4 mM caffeine, as indicated, for 2 hr. CFP-MASTL IP was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, phospho-CHK1 Ser-345, and α-tubulin.
    Figure Legend Snippet: ( A ) HeLa cells expressing CFP-MASTL were treated without or with 10 mM hydroxyurea (HU) for 2 hr. CFP-MASTL immunoprecipitation (IP) was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, and β-actin. ( B ) HeLa cells expressing CFP-MASTL were treated without or with 10 mM HU and 4 mM caffeine, as indicated, for 2 hr. CFP-MASTL IP was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, phospho-CHK1 Ser-345, and α-tubulin.

    Techniques Used: Expressing, Immunoprecipitation, Western Blot


    Structured Review

    Bethyl phosphorylated chk1 ser 345
    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) <t>Chk1</t> phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.
    Phosphorylated Chk1 Ser 345, supplied by Bethyl, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated chk1 ser 345/product/Bethyl
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast"

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    Journal: PLOS Genetics

    doi: 10.1371/journal.pgen.1010691

    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.
    Figure Legend Snippet: ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.

    Techniques Used: Spot Test, Incubation, Mutagenesis, Western Blot, SDS Page, Staining, Quantitation Assay

    ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.
    Figure Legend Snippet: ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.

    Techniques Used: Quantitation Assay, Western Blot, Mobility Shift

    (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.
    Figure Legend Snippet: (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.

    Techniques Used: Binding Assay, Mutagenesis, Spot Test, Mobility Shift

    ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.
    Figure Legend Snippet: ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.

    Techniques Used: Spot Test, Mutagenesis, Quantitation Assay, Mobility Shift


    Structured Review

    Bio-Rad phosphorylated chk1 ser 345 in chemidoc
    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) <t>Chk1</t> phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.
    Phosphorylated Chk1 Ser 345 In Chemidoc, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated chk1 ser 345 in chemidoc/product/Bio-Rad
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated chk1 ser 345 in chemidoc - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast"

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    Journal: PLOS Genetics

    doi: 10.1371/journal.pgen.1010691

    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.
    Figure Legend Snippet: ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.

    Techniques Used: Spot Test, Incubation, Mutagenesis, Western Blot, SDS Page, Staining, Quantitation Assay

    ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.
    Figure Legend Snippet: ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.

    Techniques Used: Quantitation Assay, Western Blot, Mobility Shift

    (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.
    Figure Legend Snippet: (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.

    Techniques Used: Binding Assay, Mutagenesis, Spot Test, Mobility Shift

    ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.
    Figure Legend Snippet: ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.

    Techniques Used: Spot Test, Mutagenesis, Quantitation Assay, Mobility Shift

    phospho chk1 ser 345  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc phospho chk1 ser 345
    (A) WT or E6AP KO HeLa cells were treated with or without MASTL siRNA. The cells were incubated in 0.1 μM ETO for 18 hours, and released in fresh medium for recovery. Cells were harvested at the indicated time points (after the removal of ETO) for IF using an anti-phospho-Aurora A/B/C antibody. The activation of Aurora phosphorylation (shown in red) and chromosome condensation (in blue) indicated mitosis. The percentages of cells in mitosis were quantified manually and shown. The mean values and standard deviations were calculated from three experiments. An unpaired 2-tailed Student’s t test was used to determine the statistical significance (* p<0.05, ** p<0.01, n>500 cell number/measurement). MASTL knockdown by siRNA was shown by immunoblotting in the panel E. (B) WT or E6AP KO HeLa cells with or without MASTL siRNA, as in panel A, were treated with 2 mM HU for 18 hours. Cells were then released in fresh medium, and incubated as indicated, for recovery. The cell cycle progression was analyzed by Fluorescence-Activated Cell Sorting (FACS), as described in Materials and Methods. (C) WT or E6AP KO HeLa cells were treated with or without 0.5 μM DOX for 4 hours. Cells were then analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, phospho-SMC1 <t>Ser-957,</t> <t>phospho-CHK1</t> <t>Ser-345,</t> phospho-CHK2 Thr-68, γ-H2AX and α-tubulin. (D) WT, E6AP KO, or E6AP KO with expression of HA-E6AP HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates and α-tubulin. (E) WT, E6AP KO, or E6AP KO with transfection of MASTL siRNA HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates and α-tubulin.
    Phospho Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "The ATM-E6AP-MASTL axis mediates DNA damage checkpoint recovery"

    Article Title: The ATM-E6AP-MASTL axis mediates DNA damage checkpoint recovery

    Journal: bioRxiv

    doi: 10.1101/2023.02.22.529521

    (A) WT or E6AP KO HeLa cells were treated with or without MASTL siRNA. The cells were incubated in 0.1 μM ETO for 18 hours, and released in fresh medium for recovery. Cells were harvested at the indicated time points (after the removal of ETO) for IF using an anti-phospho-Aurora A/B/C antibody. The activation of Aurora phosphorylation (shown in red) and chromosome condensation (in blue) indicated mitosis. The percentages of cells in mitosis were quantified manually and shown. The mean values and standard deviations were calculated from three experiments. An unpaired 2-tailed Student’s t test was used to determine the statistical significance (* p<0.05, ** p<0.01, n>500 cell number/measurement). MASTL knockdown by siRNA was shown by immunoblotting in the panel E. (B) WT or E6AP KO HeLa cells with or without MASTL siRNA, as in panel A, were treated with 2 mM HU for 18 hours. Cells were then released in fresh medium, and incubated as indicated, for recovery. The cell cycle progression was analyzed by Fluorescence-Activated Cell Sorting (FACS), as described in Materials and Methods. (C) WT or E6AP KO HeLa cells were treated with or without 0.5 μM DOX for 4 hours. Cells were then analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, phospho-SMC1 Ser-957, phospho-CHK1 Ser-345, phospho-CHK2 Thr-68, γ-H2AX and α-tubulin. (D) WT, E6AP KO, or E6AP KO with expression of HA-E6AP HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates and α-tubulin. (E) WT, E6AP KO, or E6AP KO with transfection of MASTL siRNA HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates and α-tubulin.
    Figure Legend Snippet: (A) WT or E6AP KO HeLa cells were treated with or without MASTL siRNA. The cells were incubated in 0.1 μM ETO for 18 hours, and released in fresh medium for recovery. Cells were harvested at the indicated time points (after the removal of ETO) for IF using an anti-phospho-Aurora A/B/C antibody. The activation of Aurora phosphorylation (shown in red) and chromosome condensation (in blue) indicated mitosis. The percentages of cells in mitosis were quantified manually and shown. The mean values and standard deviations were calculated from three experiments. An unpaired 2-tailed Student’s t test was used to determine the statistical significance (* p<0.05, ** p<0.01, n>500 cell number/measurement). MASTL knockdown by siRNA was shown by immunoblotting in the panel E. (B) WT or E6AP KO HeLa cells with or without MASTL siRNA, as in panel A, were treated with 2 mM HU for 18 hours. Cells were then released in fresh medium, and incubated as indicated, for recovery. The cell cycle progression was analyzed by Fluorescence-Activated Cell Sorting (FACS), as described in Materials and Methods. (C) WT or E6AP KO HeLa cells were treated with or without 0.5 μM DOX for 4 hours. Cells were then analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates, phospho-SMC1 Ser-957, phospho-CHK1 Ser-345, phospho-CHK2 Thr-68, γ-H2AX and α-tubulin. (D) WT, E6AP KO, or E6AP KO with expression of HA-E6AP HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates and α-tubulin. (E) WT, E6AP KO, or E6AP KO with transfection of MASTL siRNA HeLa cells were treated with or without 0.1 μM ETO, and analyzed by immunoblotting for E6AP, phospho-ATM/ATR substrates and α-tubulin.

    Techniques Used: Incubation, Activation Assay, Knockdown, Western Blot, Fluorescence, FACS, Expressing, Transfection

    (A) HeLa cells expressing CFP-MASTL were treated without or with 10 mM HU for 2 hr. CFP-MASTL IP was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, and α-tubulin. (B) HeLa cells expressing CFP-MASTL were treated without or with 10 mM HU and 4 mM caffeine, as indicated, for 2 hr. CFP-MASTL IP was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, phospho-CHK1 Ser-345, and α-tubulin.
    Figure Legend Snippet: (A) HeLa cells expressing CFP-MASTL were treated without or with 10 mM HU for 2 hr. CFP-MASTL IP was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, and α-tubulin. (B) HeLa cells expressing CFP-MASTL were treated without or with 10 mM HU and 4 mM caffeine, as indicated, for 2 hr. CFP-MASTL IP was performed using a GFP antibody. The input, GFP IP, and control (ctr) IP using blank beads were analyzed by immunoblotting for E6AP, MASTL, phospho-CHK1 Ser-345, and α-tubulin.

    Techniques Used: Expressing, Control, Western Blot

    α p chk1 ser 345  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc α p chk1 ser 345
    Key resources table
    α P Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α p chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    α p chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells"

    Article Title: TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells

    Journal: iScience

    doi: 10.1016/j.isci.2023.106405

    Key resources table
    Figure Legend Snippet: Key resources table

    Techniques Used: Recombinant, Modification, Transfection, Electrophoresis, Blocking Assay, Imaging, Purification, Software

    α p chk1 ser 345  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc α p chk1 ser 345
    Key resources table
    α P Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α p chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    α p chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells"

    Article Title: TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells

    Journal: iScience

    doi: 10.1016/j.isci.2023.106405

    Key resources table
    Figure Legend Snippet: Key resources table

    Techniques Used: Recombinant, Modification, Transfection, Electrophoresis, Blocking Assay, Imaging, Purification, Software

    α p chk1 ser 345  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc α p chk1 ser 345
    Key resources table
    α P Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α p chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    α p chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells"

    Article Title: TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells

    Journal: iScience

    doi: 10.1016/j.isci.2023.106405

    Key resources table
    Figure Legend Snippet: Key resources table

    Techniques Used: Recombinant, Modification, Transfection, Electrophoresis, Blocking Assay, Imaging, Purification, Software

    phospho chk1 ser 345 antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc phospho chk1 ser 345 antibody
    Phospho Chk1 Ser 345 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk1 ser 345 antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho chk1 ser 345 antibody - by Bioz Stars, 2024-09
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc rabbit monoclonal anti phospho chk1 ser 345
    HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, <t>CHK1,</t> CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .
    Rabbit Monoclonal Anti Phospho Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal anti phospho chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit monoclonal anti phospho chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc phospho chk1 ser 345
    HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, <t>CHK1,</t> CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .
    Phospho Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars
      Buy from Supplier

    86
    Bethyl phosphorylated chk1 ser 345
    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) <t>Chk1</t> phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.
    Phosphorylated Chk1 Ser 345, supplied by Bethyl, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated chk1 ser 345/product/Bethyl
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars
      Buy from Supplier

    86
    Bio-Rad phosphorylated chk1 ser 345 in chemidoc
    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) <t>Chk1</t> phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.
    Phosphorylated Chk1 Ser 345 In Chemidoc, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated chk1 ser 345 in chemidoc/product/Bio-Rad
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated chk1 ser 345 in chemidoc - by Bioz Stars, 2024-09
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc α p chk1 ser 345
    Key resources table
    α P Chk1 Ser 345, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α p chk1 ser 345/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    α p chk1 ser 345 - by Bioz Stars, 2024-09
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc phospho chk1 ser 345 antibody
    Key resources table
    Phospho Chk1 Ser 345 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk1 ser 345 antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho chk1 ser 345 antibody - by Bioz Stars, 2024-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .

    Journal: EMBO Reports

    Article Title: Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors

    doi: 10.1038/s44319-024-00089-7

    Figure Lengend Snippet: HCT116, HT-29 and SiHa cancer cells were chronically adapted at pH 6.5 or maintained at pH 7.4 ( A , C , D ) or native HCT116 cells were acutely exposed to acidic pH e ( B ) or treated with 5-FU at the indicated doses to be compared with cancer cells adapted at pH 6.5 ( E , F ). ( A – C ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin or tubulin was used as loading control, as indicated. ( D ) Bar graph showing the proportion of tetraploid cells. ( E , F ) Representative immunoblots of total and phosphorylated ATM, ATR, CHK1, CHK2. Actin was used as loading control, as indicated. ( G – J ) Cell viability assays in HCT116 ( G , I ) and HT-29 cancer cells ( H , J ) cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATMi AZD0156 ( G , H ) or ATRi elimusertib ( I , J ) for 72 h. Data information: ( A – J ) data represent n = 3 independent biological replicates. ( D , G – J ) Bar graphs represent means ± SD with three biological replicates ( D ) or six technical replicates ( G – J ), and significance was determined using two-way ANOVA with Tukey’s multiple-comparison analysis (ns non-significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). .

    Article Snippet: Rabbit monoclonal anti-phospho-CHK1 (Ser-345) (clone 133D3) , Cell Signaling Technology , Cat# 2348; RRID: AB_331212.

    Techniques: Western Blot, Cell Culture, Comparison

    Reagents and tools.

    Journal: EMBO Reports

    Article Title: Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors

    doi: 10.1038/s44319-024-00089-7

    Figure Lengend Snippet: Reagents and tools.

    Article Snippet: Rabbit monoclonal anti-phospho-CHK1 (Ser-345) (clone 133D3) , Cell Signaling Technology , Cat# 2348; RRID: AB_331212.

    Techniques: Membrane, Modification, Protease Inhibitor, Software, Bicinchoninic Acid Protein Assay, Viability Assay

    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.

    Article Snippet: The custom antibody against phosphorylated Chk1-Ser 345 used in this study was generated in rabbits and purified by Bethyl Laboratories (Montgomery, TX).

    Techniques: Spot Test, Incubation, Mutagenesis, Western Blot, SDS Page, Staining, Quantitation Assay

    ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.

    Article Snippet: The custom antibody against phosphorylated Chk1-Ser 345 used in this study was generated in rabbits and purified by Bethyl Laboratories (Montgomery, TX).

    Techniques: Quantitation Assay, Western Blot, Mobility Shift

    (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.

    Article Snippet: The custom antibody against phosphorylated Chk1-Ser 345 used in this study was generated in rabbits and purified by Bethyl Laboratories (Montgomery, TX).

    Techniques: Binding Assay, Mutagenesis, Spot Test, Mobility Shift

    ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.

    Article Snippet: The custom antibody against phosphorylated Chk1-Ser 345 used in this study was generated in rabbits and purified by Bethyl Laboratories (Montgomery, TX).

    Techniques: Spot Test, Mutagenesis, Quantitation Assay, Mobility Shift

    ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: ( A ) Sensitivities of the four previously reported RPA mutants to HU and MMS were examined by spot assay. A series of five-fold dilutions of the logarithmically growing cells were spotted on YE6S plates or plates containing HU or MMS. The plates were incubated at 30°C for 3 days and then photographed. Wild-type (TK48) cells and the checkpoint mutants rad3Δ (NR1826), cds1Δ (GBY191), and chk1Δ (TK197) were included as controls. ( B ) Phosphorylation of Mrc1 by Rad3 was unaffected or moderately reduced in the four RPA mutants. Wild type and the mutant cells used in A were treated with (+) or without (-) 15 mM HU for 3 h. Phosphorylation of Mrc1 (upper panel) was examined by Western blotting of whole cell lysates made from the TCA-fixed cells after SDS-PAGE using the phospho-specific antibody. The same blot was stripped and reprobed with anti-Mrc1 antibodies (middle panel). A section of the Ponceau S-stained membrane is shown for loading control (bottom panel). The phosphorylation bands were quantified, and the intensities relative to the HU-treated wild-type cells are shown at the bottom. ( C ) The Western blotting shown in B was repeated three times and the quantitation results are shown in percentages. Error bars represent the means and SDs of the triplicates. Blue and brown columns indicate before and after HU treatment, respectively. ( D ) Phosphorylation of Cds1 by Rad3 was increased or moderately reduced in the four RPA mutants. Wild type and the indicated mutant cells were treated with HU as in B. Cds1 was IPed and analyzed by Western blotting using an anti-HA antibody (bottom panel). The same membrane was stripped and then blotted with the phospho-specific antibody (upper panel). The phosphorylation bands were quantified and relative intensities are shown at the bottom. ( E ) The experiments in D were repeated three times and the quantitation results are shown. ( F ) Chk1 phosphorylation was examined in wild-type and the mutant cells treated with (+) or without (-) 0.01% MMS for 90 min. The whole cell lysates made by the TCA method were analyzed by SDS-PAGE followed by Western blotting with anti-HA antibody. ( G ) Quantitation results from three separate blots as in F are shown in ratios of phosphorylated Chk1 vs total Chk1. ( H ) Chk1 phosphorylation was examined by Western blotting using the phospho-specific antibody. Wild type and the indicated mutant cells were treated MMS as in F. Chk1 was IPed and then analyzed by Western blotting using the antibody against Chk1-pS345 (top panel). The same membrane was stripped and blotted with an anti-HA antibody (bottom panel). The relative intensities of the Chk1-pS345 bands were quantified, normalized with that of Chk1 bands, and shown in percentages. ( I ) Quantitation results from three repeats of H are shown.

    Article Snippet: After transfer to a nitrocellulose membrane, the membrane was blotted with the Chk1-pS345 antibody at the 1:3000 dilution for 3 h to detect the phosphorylated Chk1-Ser 345 in ChemiDoc (Bio-Rad).

    Techniques: Spot Test, Incubation, Mutagenesis, Western Blot, SDS Page, Staining, Quantitation Assay

    ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: ( A ) Rad3-dependent Mrc1 phosphorylation in the thirteen ssb1 mutants was examined as in (left panels). Quantitation results from three repeats are shown on the right. ( B ) Rad3-dependent Cds1 phosphorylation in the ssb1 mutants was examined (left panels), repeated three times, and the quantitation results are shown on the right. ( C ) Rad3-dependent Chk1 phosphorylation in the ssb1 mutants treated with MMS was examined by Western blotting using the phospho-specific antibody as in . The quantitation results are shown on the right. ( D ) The Chk1 phosphorylation in the MMS-treated ssb1 mutants was examined by the mobility shift assay as in . The quantitation results are shown on the right.

    Article Snippet: After transfer to a nitrocellulose membrane, the membrane was blotted with the Chk1-pS345 antibody at the 1:3000 dilution for 3 h to detect the phosphorylated Chk1-Ser 345 in ChemiDoc (Bio-Rad).

    Techniques: Quantitation Assay, Western Blot, Mobility Shift

    (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: (A) Diagram of Ssb1 and the relative positions of amino acid changes caused by the mutations. The four DNA binding domains F, A, B, and C are shown in blue. The intensively screened N-terminal region containing the F domain is enlarged. Dots indicate the relative locations of the mutated amino acid residues. While the yellow dots indicate the mutations that were identified once, the purple dots are those that were identified at least two times in separate mutants. The red dot indicates ssb1-R46E mutation that is analogous to the budding yeast rfc1-t11 in S . pombe . (B) The cell growth, drug sensitivities, Ssb1 levels, and checkpoint defects of the twenty-five primary ssb1 mutants identified in this study. The number of the primary mutants and their mutations are shown in the 1 st and 2 nd columns from the left, respectively. Numbers in parentheses indicate the times the mutants were independently screened. Asterisks in the 3 rd column indicate the relative cell growth status estimated on YE6S plates in the spot assays (Figs and ). Relative sensitivities to chronic (Figs and ) and acute HU treatment (Figs and ) determined by spot assay are shown by the asterisks in the 4 th and 5 th columns, respectively. R: resistance; UD: undetectable or minimal sensitivity. Relative Ssb1 levels in logarithmically growing cells were shown in the 7 th column. The numbers in parentheses are SD values of three repeats. Similarly, phosphorylation Mrc1 and Cds1 in HU are shown in the 8 th and 9 th columns, respectively. Chk1 phosphorylations determined by phospho-specific antibody and the mobility shift assay are shown in the 10 th and 11 th columns, respectively. The numbers in the highlighted twelve mutants in the 11 th column (lower part) were from a separate experiment. The ratio of pChk1/total Chk1 in wild-type control for the twelve mutants is 43.1 ± 4.7 (n = 3). The six primary mutants selected for further characterization are marked by the dots on the left. The two mutants with confirmed partial DRC defects are marked by the green dots. The red dots indicate the mutants whose “checkpoint defects” are caused by secondary mutations. Brown dots are those with largely intact checkpoints.

    Article Snippet: After transfer to a nitrocellulose membrane, the membrane was blotted with the Chk1-pS345 antibody at the 1:3000 dilution for 3 h to detect the phosphorylated Chk1-Ser 345 in ChemiDoc (Bio-Rad).

    Techniques: Binding Assay, Mutagenesis, Spot Test, Mobility Shift

    ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.

    Journal: PLOS Genetics

    Article Title: Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast

    doi: 10.1371/journal.pgen.1010691

    Figure Lengend Snippet: ( A ) Six primary ssb1 mutants with more prominent checkpoint defects were selected. Their mutations were confirmed by integrating at the genomic locus in a wild-type strain. Drug sensitivities of the integrants referred to as ssb1-1 , ssb1-7 , ssb1-10 , ssb1-17 , ssb1-19 , and ssb1-24 were examined by spot assay and compared with their corresponding primary mutants. Dashed lines indicate the discontinuity. Phosphorylation of Mrc1 ( B) and Cds1 ( C ) in the six mutant integrants was examined as in . Quantitation results from three independent blots are shown in , respectively. Chk1 phosphorylation in the six integrants was examined as in by phospho-specific antibody ( D) and by mobility shift assay (E ) and the quantitation results are shown in , respectively. Rad9 phosphorylation was examined in IPed samples using the phospho-specific antibody in the presence of HU ( F) or MMS (G ). Quantitation results are shown in , respectively.

    Article Snippet: After transfer to a nitrocellulose membrane, the membrane was blotted with the Chk1-pS345 antibody at the 1:3000 dilution for 3 h to detect the phosphorylated Chk1-Ser 345 in ChemiDoc (Bio-Rad).

    Techniques: Spot Test, Mutagenesis, Quantitation Assay, Mobility Shift

    Key resources table

    Journal: iScience

    Article Title: TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells

    doi: 10.1016/j.isci.2023.106405

    Figure Lengend Snippet: Key resources table

    Article Snippet: 8 hours later, the media of the cells was exchanged for antibiotic-containing media and cells were either transfected again or harvested for experiments 72 hours later. . Antibody sources α-GAPDH (# PAB17013 , Abnova), α-γH2A.x Ser 139 (JBW301, #05-636, Millipore), α-Myc-tag (9B11, #2276S, Cell Signaling), α-p-Chk1 Ser 345 (133D3, #2348S, Cell Signaling), α-PML (#sc-5621, Santa Cruz) α-p-Chk2 Thr 68 (#2661S, Cell Signaling), α-p-ATR Thr 1989 (#ab223258, Abcam), α-p-ATM Ser 1981 (D25E5, #13050S, Cell Signaling), α-ATRX (#sc-15408, Santa Cruz), α-DAXX (#sc-7152, Santa Cruz), α-H3.3 (#ab176840, Abcam), α-RMI1 (#NB100-1720, Novus), α-FLAG-tag (M2, #F1804-1MG, Sigma), α-RPA32 (9H8, #ab2175, Abcam), α-RPA70 (#sc-28304, Santa Cruz). α-BLM (R7019), α-TRF1 (R6839) and α-TRF2 (R6841) were raised in our lab. All antibodies were used for Western Blotting apart from α-BLM, α-Myc and α-FLAG that were also used for IF and α-RPA32, α-RPA70, α-PML, α-TRF1 and α-TRF2 that were used for IF only.

    Techniques: Recombinant, Modification, Transfection, Electrophoresis, Blocking Assay, Imaging, Purification, Software